PD-1和PD-L1在Ⅳ<sub> a</sub>期鼻咽癌组织中的表达及临床意义

doi:10.3760/cma.j.issn.1004-4221.2017.10.005

摘要
图/表
参考文献()
相关文章 (9)
点击分布统计
下载分布统计

全文: PDF (2453 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的检测鼻咽癌组织中PD-1和PD-L1的表达水平,探讨PD-1和PD-L1表达水平与鼻咽癌患者临床特征及预后关系。方法应用免疫组织化学方法检测65例Ⅳ_a期鼻咽癌患者肿瘤组织中PD-1和PD-L1表达水平,分析两者表达水平与患者临床特征及长期生存间关系。对组间比较行χ²检验或Fisher′s精确概率法,相关分析采用Pearson检验;采用Kaplan-Meier进行生存分析,Logrank法检验和单因素预后分析,Cox模型多因素预后分析。结果阳性阈值为5%时肿瘤细胞表面PD-1和PD-L1阳性表达率分别为88%(57/65)、89%(58/65),两者表达水平显著相关(P=0.003);阳性阈值为10%时肿瘤细胞表面PD-1和PD-L1阳性表达率分别为38%(25/65)、58%(38/65),两者表达水平趋于相关(P=0.080)。不同水平PD-1和PD-L1阳性表达与临床病理特征无关(P>0.05)。单因素和多因素生存分析显示阳性阈值定为10%时PD-L1阳性表达者OS及PFS均较PD-L1阴性者短(OS:HR=3.95,95%CI为1.09~14.27,P=0.036;PFS:HR=2.73,95%CI为1.07~6.97,P=0.035)。结论 PD-1和PD-L1在鼻咽癌组织中呈高表达水平,且PD-L1表达水平与Ⅳ_a期鼻咽癌患者不良预后相关,在阳性阈值为10%时可更好地预测预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：程序性死亡, 程序性死亡配体, 鼻咽肿瘤/放化疗法, 预后基金项目:新疆维吾尔自治区重点实验室项目(2015KL021)

Abstract：

Objective To measure the expression levels of PD-1 and PD-L1 in the tumor tissues of patients with nasopharyngeal carcinoma (NPC) and to explore the association of their expression with the clinical characteristics and prognosis of NPC patients. Methods The expression levels of PD-1 and PD-L1 in 65 NPC patients were determined by immunohistochemistry, and an analysis was performed on the association of their expression with clinical characteristics and long-term survival in NPC patients. Comparisons between groups were made by the chi-square test or Fisher′s exact test, and the Pearson’s test was used for correlation analysis. Survival rates were calculated using the Kaplan-Meier method, and the log-rank test was used for survival comparison and univariate prognostic analysis. The Cox model was used for multivariate prognostic analysis. Results Expression of PD-1 and PD-L1 was observed in 88%(57/65) and 89%(58/65) of tumor cell surfaces using a cut-off value of 5%, and 38%(25/65) and 58%(38/65) using a cut-off value of 10%. PD-1 expression was significantly correlated with PD-L1 expression using the cut-off value of 5%(P=0.003), and a non-significant correlation was found between the expression levels of PD-1 and PD-L1 using the cut-off value of 10%(P=0.080). There was no significant association between the positive expression rates of PD-1 and PD-L1 and clinicopathological characteristics (P>0.05). The univariate and multivariate survival analyses showed that using the cut-off value of 10%, the patients with positive PD-L1 expression had significantly reduced progression-free survival (hazard ratio[HR]=2.73, 95% confidence interval[CI]:1.07-6.97, P=0.035) and overall survival (HR=3.95, 95%CI:1.09-14.27, P=0.036) compared with those with negative PD-L1 expression. Conclusions PD-1 and PD-L1 are highly expressed in NPC tissues. The expression of PD-L1 is associated with the poor prognosis in patients with stage IVa NPC, and PD-L1 can better predict the poor prognosis using the cut-off value of 10%.

Key words： Programmed death Programmed death ligand Nasopharyngeal neoplasms/radiochemotherapy Prognosis

收稿日期: 2017-04-08

通讯作者: 王若峥,Email:wrz8526@vip.163.com

引用本文:

. PD-1和PD-L1在Ⅳ_a期鼻咽癌组织中的表达及临床意义[J]. 中华放射肿瘤学杂志, 2017, 26(10): 1131-1136.

. Expression of PD-1 and PD-L1 in patients with stage Ⅳ_{a nasopharyngeal carcinoma and its clinical significance}[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1131-1136.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.10.005 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I10/1131

[1] Wang R,Tan Y,Wang X,et al. Prognoses and long-term outcomes of nasopharyngeal carcinoma in han and uyghur patients treated with intensity-modulated radiotherapy in the xinjiang autonomous region of China[J/OL].Plos One,2014,9(11):e111145.DOI:10.1371/journal.pone.0111145.
[2] 区晓敏,史琪,周鑫,等.鼻咽癌IMRT远期疗效和不良反应分析[J].中华放射肿瘤学杂志,2016,25(4):304-309.DOI:10.3760/cma.j.issn.1004-4221.2016.04.002.
Ou XM,Shi Q,Zhou X,et al. Analysis of long term efficacy and adverse reactions of nasopharyngeal carcinoma IMRT[J].Chin J Radiat Oncol,2016,25(4):304-309.DOI:10.3760/cma.j.issn.1004-4221.2016.04.002.
[3] 易俊林,高黎,黄晓东等.416例鼻咽癌调强放疗远期生存与影响因素分析[J].中华放射肿瘤学杂志,2012,21(3):196-200.DOI:10.3760/cma.j.issn.1004-4221.2012.03.002.
Yi JL,Gao L,Huang XD,et al. Long term survival and influencing factors of intensity-modulated radiotherapy for nasopharyngeal carcinoma:a report of 416 cases[J].Chin J Radiat Oncol,2012,21(3):196-200.DOI:10.3760/cma.j.issn.1004-4221.2012.03.002.
[4] Lee AW,Ma BB,Ng WT,et al. Management of Nasopharyngeal Carcinoma:Current Practice and Future Perspective[J].J Clin Oncol.2015,33(29):3356-64.DOI:10.1200/JCO.2015.60.9347.
[5] Jin Y,Shi YX,Cai XY,et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma[J].J Cancer Res Clin Oncol,2012,138(10):1717-25.DOI:10.1007/s00432-012-1219-x.
[6] Hawkes EA,Grigg A,Chong G.Programmed cell death-1 inhibition in lymphoma[J].Lancet Oncol,2015,16(5):e234-e245.DOI:10.1016/S1470-2045(15)70103-8.
[7] 王倩蓉,李宝生.PD-1/PD-L1单抗联合放疗治疗实体瘤研究进展[J].中华放射肿瘤学杂志,2016,25(12):1375-1378.DOI:10.3760/cma.j.issn.1004?4221.2016.12.022.
Wang QR,Li BS.Research progress of PD-1/PD-L1 monoclonal antibody combined with radiotherapy for solid tumors[J].Chin J Radiat Oncol,2016,25(12):1375-1378.DOI:10.3760/cma.j.issn.1004?4221.2016.12.022.
[8] Kwon ED,Drake CG,Scher HI,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.DOI:10.1016/S1470-2045(14)70189-5.
[9] Ohaegbulam KC,Assal A,Lazar-Molnar E,et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.DOI:10.1016/j.molmed.2014.10.009.
[10] Swaika A,Hammond WA,Joseph RW.Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J].Mol Immunol,2015,67(2):4-17.DOI:10.1016/j.molimm.2015.02.009.
[11] Chow L Q,Haddad R,Gupta S,et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Results From the Phase Ib KEYNOTE-012 Expansion Cohort[J].J Clin Oncol,2016,34(32):3838-3845.DOI:10.1200/JCO.2016.68.1478.
[12] Fang W,Zhang J,Hong S,et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy[J].Oncotarget,2014,5(23):12189-202.DOI:10.18632/oncotarget.2608.
[13] Zhang J,Fang W,Qin T,et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma[J].Med Oncol.,2015,32(3):1-6.DOI:10.1007/s12032-015-0501-6.
[14] Lee VHF,Lo AWI,Leung CY,et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic sasopharyngeal carcinoma[J/OL].Plos One,2016,11(6):e0157969.DOI:10.1371/journal.pone.0157969.
[15] Kleffel S,Posch C,Barthel S,et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth[J].Cell,2015,162(6):1242. DOI:10.1016/j.cell.2015.08.052.
[16] Zhou Y,Miao J,Wu H,et al. PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma:the correlation with anemia and outcomes[J].Oncotarget,2017.DOI:10.18632/oncotarget.17214.
[17] Chan OS,Kowanetz M,Ng WT,et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.[J].Oral Oncol,2017,67:52-60. DOI:10.1016/j.oraloncology.2017.02.002.
[18] Zhang Y,Kang S,Shen J,et al. Prognostic significance of programmed cell death 1(PD-1) or PD-1 ligand 1(PD-L1) Expression in epithelial-originated cancer:a meta-analysis[J].Medicine,2015,94(6):e515. DOI:10.1097/MD.0000000000000515.
[19] Zhou Y,Shi D,Miao J,et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load[J].Sci Rep,2017,7:43627. DOI:10.1038/srep43627.